Deutsche Bank AG Takes Position in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV)

Deutsche Bank AG bought a new stake in shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 21,423 shares of the company’s stock, valued at approximately $216,000. Deutsche Bank AG owned 0.09% of Artiva Biotherapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently made changes to their positions in the business. Charles Schwab Investment Management Inc. grew its stake in Artiva Biotherapeutics by 8.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 43,526 shares of the company’s stock worth $439,000 after purchasing an additional 3,233 shares during the period. Wells Fargo & Company MN grew its stake in Artiva Biotherapeutics by 64.0% in the fourth quarter. Wells Fargo & Company MN now owns 8,616 shares of the company’s stock worth $87,000 after purchasing an additional 3,361 shares during the period. Northern Trust Corp grew its stake in Artiva Biotherapeutics by 3.8% in the fourth quarter. Northern Trust Corp now owns 117,112 shares of the company’s stock worth $1,180,000 after purchasing an additional 4,335 shares during the period. Barclays PLC grew its stake in Artiva Biotherapeutics by 23.2% in the fourth quarter. Barclays PLC now owns 24,161 shares of the company’s stock worth $244,000 after purchasing an additional 4,545 shares during the period. Finally, China Universal Asset Management Co. Ltd. purchased a new stake in Artiva Biotherapeutics in the fourth quarter worth $52,000.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. Needham & Company LLC reduced their price target on Artiva Biotherapeutics from $23.00 to $18.00 and set a “buy” rating on the stock in a research note on Thursday, May 15th. Cantor Fitzgerald reduced their price target on Artiva Biotherapeutics from $23.00 to $20.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 25th. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of Artiva Biotherapeutics in a research note on Wednesday, March 26th. Finally, Wedbush reissued an “outperform” rating and issued a $18.00 target price on shares of Artiva Biotherapeutics in a report on Tuesday, March 25th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $19.40.

Artiva Biotherapeutics Price Performance

Artiva Biotherapeutics stock opened at $1.94 on Tuesday. The business’s fifty day simple moving average is $2.27 and its two-hundred day simple moving average is $5.74. Artiva Biotherapeutics, Inc. has a 12 month low of $1.78 and a 12 month high of $17.31.

Artiva Biotherapeutics (NASDAQ:ARTV) last released its earnings results on Thursday, May 8th. The company reported ($0.83) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.15). Sell-side analysts predict that Artiva Biotherapeutics, Inc. will post -4.95 earnings per share for the current year.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.